V.C.F.

Tracking what moves markets: earnings, catalysts, institutional calls & breaking headlines. Not Financial Advice.

[V.C.F. @VcircleFuture]

The market keeps treating $GRMN like a simple GPS watch maker.

Tigress Financial just raised their PT to $310, highlighting the disconnect.

Here’s what they see that others are missing:

→ The Core Thesis: Multiple growth drivers, resilient profitability, and high-quality capital allocation demand a premium valuation. Not a cyclical hardware play.

→ Beyond the Wrist: Deepening its moat in high-margin niches like defense avionics (Brazilian Air Force UH-60 upgrade) and off-grid connectivity (inReach Mini 3).

→ The Real Hidden Asset: A massive Garmin Connect data set being monetized. The pivot from fitness tracking to clinically relevant, AI-driven health insights is the game-changer.

→ Financial Fortress: Record revenue, broad-based double-digit growth, and a strong balance sheet fueling R&D, M&A, dividends, and buybacks. A capital allocation machine.

[V.C.F. @VcircleFuture]

Wedbush turns sharply bearish on $LYFT.

→ Rating: Slashed from Neutral to Underperform.
→ Price Target: Cut to $16, down from $20.
→ The AV Threat: Wedbush sees an existential risk from Autonomous Vehicles. $LYFT's undiversified, US-only model is uniquely vulnerable as AV operators build their own 1P distribution, making aggregators obsolete.
→ The Valuation Error: The market is completely underestimating the "negative terminal value" impact that AVs will have on $LYFT's DCF.
→ The Growth Miss: Investor confidence is fading. Core business growth is already tracking at a 12.6% CAGR ('24-'27), a full 240bps below the company's own 15% target.

[V.C.F. @VcircleFuture]

Deutsche Bank sees downside for $ELV, downgrading to Hold.

→ New PT: $320, a cut from $332 and below the current ~$345 share price.
→ The 2025 guidance of ~$30 EPS is misleading. Strip out ~$3 in one-offs and the 2026 baseline is just ~$27.
→ DB's own 2026 EPS model is even worse at $26.72, 11% lower and below consensus.
→ Headwinds are piling up: regulatory uncertainty, rising utilization, and a challenging rate environment.
→ The biggest risk: ACA membership is projected to "decline sharply" as government subsidies expire.
→ The verdict: 2026 is a "transition year." The market may not have priced in the execution risk.

[V.C.F. @VcircleFuture]

The market is obsessed with AI chips. Meanwhile, the company making the complex boards they sit on gets a PT hike to $91.

Inside the Truist Buy call on $TTMI:

→ The Real AI Exposure: Not a story stock. Nearly 30% of revenue is already tied to AI workloads across data centers and networking.

→ The Demand Shock: Customers are signaling a near doubling of PCB layer counts for next-gen AI systems. Complexity is exploding.

→ The Bottleneck: $TTMI is a critical enabler in hyperscale infrastructure. A non-negotiable part of the stack.

→ Diversified Growth: Beyond the AI narrative, you get a solid defense business (Syracuse) and future capacity ramp (Penang).

→ The Street-High Call: Truist's EPS estimates are the highest on the Street, betting the market is missing the compounding growth levers.

[V.C.F. @VcircleFuture]

The market was worried about the AI hardware "soft patch."
Meanwhile, $MPWR was just reloading.

Truist sees it, hiking their Price Target 18% to $1,375.

→ The supposed "soft patch" in their AI segment is over. Now back to growth & represents ~30% of total revenue.

→ A "layering effect" of new GenAI customers is driving re-acceleration. This isn't a one-off hit.

→ Next-gen GPUs are power-hungry beasts. $MPWR’s proprietary power solutions are the critical, non-negotiable plumbing.

→ Their addressable market in AI datacenters is already $4B+, and they're expanding into new power distribution systems.

→ This isn't just another chip stock. It's a high-margin bottleneck for the entire AI infrastructure buildout.

[V.C.F. @VcircleFuture]

Wedbush just hiked its $RIVN price target 56% to $25.

They're telling you to ignore the 2024 cash burn and focus entirely on the 2026 setup.

The bull case:
→ R2 is the Inflection Point: Launch in 1H26 expected to fundamentally change delivery volume.
→ Beyond Selling Trucks: Tapping into the autonomy roadmap for new revenue streams.
→ "Strategic" Cost Structure: A bet they can manage rising tariff risks while funding the ramp.
→ The Trade: Look past the near-term noise for a 2026 re-rating. A classic "show me" story.

[V.C.F. @VcircleFuture]

H.C. Wainwright initiates on $CRCL with a classic "great company, not a great stock" argument.

→ The Bull Case: Calls USDC a "best-of-breed" product in a winner-takes-most market. Praises its regulatory moat as a key differentiator.

→ The Contradiction: Despite the massive TAM and strong product, the current valuation already "fully reflects" the entire near-term opportunity.

→ The Headwinds: Needs a "step function change" in USDC supply to offset margin compression from Fed rate cuts and rising distribution costs.

→ The Verdict: Neutral rating with an $85 PT. All the hype is already in the price, offering "limited upside" from here. A wait-and-see story.

[V.C.F. @VcircleFuture]

Wells Fargo upgrades $GNRC to Overweight, PT $195.
The thesis highlights a glaring market oversight on the AI power story.

→ The Catalyst: The AI data center buildout requires an explosion in backup power. $GNRC’s diesel gensets are a key beneficiary.

→ The Mispricing: The market is currently pricing this entire data center opportunity at a laughable ~$4/share.

→ The Potential: Wells Fargo calculates the segment is actually worth $61/share if $GNRC captures just 10% of the $12B annual TAM.

→ The Numbers: The stock reflects <$300MM in future revenue from this. WF's 5-year average estimate is $1.2B. A 4x disconnect.

[V.C.F. @VcircleFuture]

The market is selling $SPOT on AI fears and macro jitters.
BofA calls the weakness a "particularly attractive opportunity."

A classic disconnect between narrative and numbers:
→ Market Obsession: Fretting over the timing of a US price hike.
→ Analyst Reality: Delay is not weakness. Global engagement is growing, and price hikes elsewhere were absorbed with minimal churn.

→ The Fear: Broader tech sell-off and vague "AI risk" weighing on the stock.
→ The Call: Reiterate Buy rating with a massive $900 PT, citing strong KPI momentum.

Selling a story while ignoring the fundamentals.

[V.C.F. @VcircleFuture]

BofA sees a major disconnect between the market's hype for $HIMS and the underlying data.

→ The Street consensus for 2026 requires an incremental $440MM in online revenue, a target BofA calls a major hurdle.
→ Key performance indicators are flashing warning signs: orders and app downloads are "generally weak."
→ The entire bull thesis now hinges on the trajectory of GLP-1 sales, a massive bet to justify current valuation.
→ While new investments in labs/SKUs might pay off eventually, they don't solve the near-term revenue gap.
→ BofA maintains its Underperform rating and $32 PT, signaling the growth story is overextended.

[V.C.F. @VcircleFuture]

BTIG initiates on $CCEC with a Buy rating and a $25 PT.
The thesis: A massive LNG infrastructure super-cycle is underway.

→ Global LNG liquefaction capacity is set for ~40% growth, hitting ~700mtpa by 2030, driven by the US & Qatar.

→ The market contradiction: While Asian LNG demand is tracking down 3-5% for 2025, global demand is expected to be up 3-4% as Europe absorbs the volume.

→ The long game: Don't get faked out by the short-term dip. Over the next five years, Asian demand alone is expected to add over 200mtpa.

[V.C.F. @VcircleFuture]

$SERV up ~7% today

[V.C.F. @VcircleFuture]

Oppenheimer just dropped a massive call on a small-cap robotics name.

They're initiating on $SERV with a $20 price target, implying a ~400%+ upside from current levels.

The market is either asleep, or the analyst is dreaming.

Here's the thesis:

→ Call: Initiates with Outperform rating and a $20.00 price target.

→ The Angle: $SERV isn't just a delivery bot company; it's a "Physical AI pioneer" targeting the last-mile.

→ The Moat: It has "global data leadership" on complex sidewalks, giving it an edge in hardware and software efficiency.

→ The Payoff: This data supremacy translates to structural cost advantages and accelerated learning cycles vs. all peers.

[V.C.F. @VcircleFuture]

$HUT up ~17% today

[V.C.F. @VcircleFuture]

Canaccord getting aggressive on $HUT. The interesting part isn't the PT bump, but the reason why. The market is shifting from pricing hype to pricing signed deals.

→ New Target: $62 (from $54), maintaining a Buy. This is their second PT raise since early November.

→ The entire $8 increase is from re-valuing just one project: River Bend.

→ Old method: Valued at ~$14/share using peer comps for similar AI hosting agreements. A guesstimate.

→ New method: Valued at ~$22/share using a DCF on the now-signed contract terms. The difference between a guess and a deal.

→ Note the math: The DCF uses an attractive 8% WACC, justified by expected SOFR + 2.5% project financing. Cheap capital is a powerful catalyst.

[V.C.F. @VcircleFuture]

Morgan Stanley on $ALB: The definition of a mixed signal. They hold an Equalweight rating but the numbers are moving.

→ Maintains a neutral $147 PT, but quietly hikes Q4'25 EBITDA estimate by a massive 33% to $221M.

→ The bull case: Bumping their Chinese lithium price forecast to $11,768/t, boosting expected Energy Storage margins to 22.7%.

→ The irony: Notes improved sentiment from China canceling 27 expired mining permits, but clarifies it has zero impact on supply as the mines were already offline. A nothingburger rally.

→ The bear case: Expects a major miss in the Specialties segment, forecasting $38M in EBITDA vs. a lofty $58M consensus.

→ The contradiction: MS is now above the Street on 2026 EBITDA ($1.45B vs $1.31B consensus) yet remains on the sidelines. Someone's model is wrong.

[V.C.F. @VcircleFuture]

Evercore sees a massive valuation disconnect in $ODD.

While the market sleeps, the fundamentals are screaming.

→ Thesis: An "unusually attractive" 9x EV/EBITDA multiple for a Rule-of-40 machine.

→ The Track Record: 10 consecutive quarters of 20%+ revenue growth and 9 quarters of ~20% EBITDA margins. Consistency is ignored.

→ The Catalyst: New skincare line METHODIQ shows "strong early traction." Evercore projects it could add $80M-$200M in new revenue by 2028.

→ The Upside: That new revenue represents an 8-14% upside to current Street estimates.

→ The Conviction: Evercore reiterates its Outperform rating, $80 PT, and calls $ODD one of its Top 3 SMID Cap Longs.

[V.C.F. @VcircleFuture]

Jefferies isn't backing down from $NKE. They're reiterating a Buy with a $115 PT.

The market remains fixated on the China drag while ignoring the operational discipline taking hold.

→ Progress where it matters most: North America & EMEA are seeing traction from innovation and distribution changes.
→ A cleaner story: Total sales are up for the 2nd consecutive quarter with controlled inventory, signaling a better supply/demand balance.
→ Margin management: Gross margin declines are improving and SG&A is being "very well controlled." This is the quiet execution the market is missing.
→ The big question: China remains challenged on revenue and EBIT. Jefferies admits a bottom "will take time."
→ The setup: A core business showing signs of a turn, trading on sentiment from one challenged geography. A classic disconnect.

[V.C.F. @VcircleFuture]

Wall Street finally putting a price on air superiority. KeyBanc initiates on $AVAV with a chunky $285 target.

They argue the market is under-appreciating a best-in-class defense tech leader.

The bull case in 4 points:
→ Pure-play exposure to secular growth in defense tech and space.
→ A deep moat built on a massive defense backlog and the strategic BlueHalo acquisition.
→ Industry-leading margins that most competitors can't touch.
→ Smart expansion into the high-growth cUAS/interceptor market.

Valuation logic: Trades at ~28x EV/EBITDA. The $285 PT is based on a premium ~34x multiple on blended 2026/2027 estimates. The thesis is you have to pay up for quality.

[V.C.F. @VcircleFuture]

The market is selling $BIIB on Alzheimer's data timing fears.
RBC Capital sees a top large-cap pick for 2026. The disconnect:

→ RBC reiterates Outperform, PT $210, while the stock languishes below $170.

→ The street obsesses over the timing of $LLY's pre-symptomatic Alzheimer's data, interpreting delays as a sign of weaker efficacy.

→ The real story is a deeply underappreciated pipeline. $BIIB is advancing a new BTK degrader, BIIB145, for Multiple Sclerosis.

→ This pushes $BIIB into the transformative protein degradation space, with a potentially superior mechanism in a market they already dominate.

→ The valuation gap: RBC sees 15%+ upside from a new MS drug alone, and another +25% if $LLY's data is positive, with limited downside risk.

→ Classic mispricing: The market is focused on a single catalyst's timing while ignoring a stabilizing core business and a de-risked I&I portfolio.

[V.C.F. @VcircleFuture]

$CMG's new strategy isn't about burritos. It's about Ozempic.

Goldman Sachs reiterates its Buy rating, but the real story is how a fast-food chain is becoming a pharma-adjacent play.

→ $CMG is launching a "High Protein Menu" explicitly targeting the behavioral shifts of GLP-1 drug users.

→ New lineup includes an 81g protein "Double High Protein Bowl" and a 32g protein "High Protein Cup" for a national average of $3.82.

→ The goal: Create a new, low-ticket "snack" occasion to drive traffic frequency beyond just lunch and dinner rushes.

→ The thesis is simple: Sell high-satiety, macro-friendly food to the millions of people whose appetites are being suppressed by medication.

A burrito chain's growth story is now tied to a blockbuster weight-loss drug. You can't make this up.

[V.C.F. @VcircleFuture]

Another day, another $NVDA price target hike.

Tigress bumps to $350. The bull case is becoming almost comically simple:

→ Calls it the "premier AI investment"—less a company, more the core AI engine powering global infrastructure.

→ The "AI flywheel" is just accelerating, fueled by GPU innovation that drives record profitability and massive FCF.

→ The real alpha? The market is still sleeping on its healthcare division, an "underappreciated growth driver."

→ It’s a near-monopoly play on a "several hundred billion dollar" market. Do the math.